Fig. 1
From: KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner
MRTX1257 radio-sensitizes in vitro CT26 and LL2 tumor cell lines according to their KRAS mutational status. Clonogenic survival assays were performed after treatment using RT and MRTX1257 at various doses in different cell lines harboring different KRAS mutational profiles. Normalized survival fractions are represented in mean ± standard-error to mean (SEM), with n = 3 to 6 replicates per condition. Survival curves are extrapolations according to the linear quadratic model. ****: p < 0.0001 (one-way ANOVA). Survival curves for (A) CT26 KRASG12C+/+; B CT26 WT; C LL2 NRAS−/−; D LL2 WT. E, F Dose–response curves for CT26 WT and LL2 WT cell lines exposed to various concentrations of KRAS.G12C inhibitor MRTX1257